Capping a series of investments designed to boost its manufacturing footprint, Novo Nordisk has said it will spend around $550 million to increase output in Chi 20 March 2024
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
Firms with an interest in artificial intelligence (AI), such as Microsoft and Nvidia, led US stock markets to new heights last year, as investors sought to pric 15 March 2024
Britain’s health technology assessor (HTA) is moving to recommend against funding Casgevy (exagamglogene autotemcel), the second such blow for people with sickl 15 March 2024
More than a year later than expected, Sino-American oncology specialist BeiGene has at last secured US approval for its novel checkpoint inhibitor, tislelizumab 15 March 2024
USA-based Insmed (NASDAQ CM: INSM) is a biopharmaceutical company on the development and commercialization of novel, targeted inhaled therapies for patients with serious rare diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news